Efficacy of Treatment for Crohn's Disease

Abstract

In this presentation, we explore the efficacy and safety of treatment options for moderate to severe Crohn's disease through the analysis of previously published scientific literature.  We have found through our secondary analysis that Ustekinumab (Stelara) has a rapid mechanism of action and therefore might be beneficial for rapid improvement in a patient. Recent reviews have shown that Ustekinumab ranked highest for initiation of remission in patients. From this specific research, there have been some conclusions that Ustekinumab should be the preferred treatment option after the failure of an Anti-TNF option. No significant differences were found when a comparison of Infliximab and Ustekinumab was carried out, but it was found that patients treated with Ustekinumab had a higher rate of steroid-free remission. Ustekinumab can be used as a first or second line of treatment and is beneficial for specific subpopulations. Although these conclusions have been determined, there still needs to be more drug-to-drug comparisons to standardize treatment and/or management options.